Compugen Ltd (CGEN) stock
CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.96−0.06 (-2.97%)
Close on Nov 18, 2026Market cap $185.32MP/E 5.2Yield –
Compugen free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was $31.33M, down 36.7% from the year before. The highest annual figure on record is $49.49M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.33M | -36.7% |
| FY2024 | Dec 31, 2024 | $49.49M | – |
| FY2023 | Dec 31, 2023 | -$36.06M | – |
| FY2022 | Dec 31, 2022 | -$34.59M | – |
| FY2021 | Dec 31, 2021 | -$22.98M | – |
| FY2020 | Dec 31, 2020 | -$28.49M | – |
| FY2019 | Dec 31, 2019 | -$28.04M | – |
| FY2018 | Dec 31, 2018 | -$13.45M | – |
| FY2017 | Dec 31, 2017 | -$31.04M | – |
| FY2016 | Dec 31, 2016 | -$22.42M | – |
| FY2015 | Dec 31, 2015 | -$28.73M | – |
| FY2014 | Dec 31, 2014 | -$13.04M | – |
| FY2013 | Dec 31, 2013 | -$6.77M | – |
| FY2012 | Dec 31, 2012 | -$11.85M | – |
| FY2011 | Dec 31, 2011 | -$9.35M | – |
| FY2010 | Dec 31, 2010 | -$4.33M | – |
| FY2009 | Dec 31, 2009 | -$7.50M | – |
See a number that looks wrong?